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Abstract
Oncologic outcomes of radical prostatectomy in 106 patients with clinically locally advanced prostate cancer were demon-
strated. The mean follow-up was 50.6 (12−129) months. 5-year recurrence-free survival was 47.7 %, 5-year cancer-specific and 
overall survival − 85.8 %. Patients were devided into three different risk groups: low risk patients had PSA level <20 ng/ml, biopsy 
Gleason score ≤6 and absence of the seminal vesicle invasion of cancer; intermediate risk was noted when the patient had only one of 
poor prognostic factors (PSA ≥20 ng/ml or biopsy Gleason score ≥7 or presence of cancer invasion to the seminal vesicle) and high 
risk patients had 2 or 3 poor prognostic factors. For patients of  low, intermediate and high risk the biochemical reccurence rates were 
14.3 %, 37.1 % and 70.2 %, respectively (p=0.002). The patients of intermediate and high risk had clinically significant higher risk 
of biochemical reccurence than those of low risk with odds ratio 3.0 and 8.5, respectively. Such grouping may help in guiding the 
individualized treatment for these patients.
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1. Introduction
Locally advanced prostate cancer (PCa) is defined as a tumor that has extended beyond the 
prostatic capsule, including invasion of the periprostatic fat, bladder neck or seminal vesicles, but 
without regional or distant metastases. Nearly 20−25 % of cases present as locally advanced dis-
ease [1, 2]. Last years the incidence of PCa in locally advanced stage significantly decreased, pri-
marily due to the early diagnosis improvement through the use of prostate-specific antigen (PSA) 
and needle biopsy. In 2013 in Ukraine, the percentage of locally advanced disease in the prostate 
cancer incidence was 23.1 % compared with 31.1 % in 2003 [3, 4].
The management of locally advanced PCa is one of the most compelling contemporary 
challenges. In the absence of randomized clinical trials comparing the effectiveness of radical 
prostatectomy (RPE), radiotherapy (RT), androgen deprivation therapy (ADT), or combination of 
these methods, it is difficult to determine the optimal treatment strategy for these patients. RPE 
with an extended pelvic lymphadenectomy is a proper treatment option of patient with locally 
advanced PCa accepted by international guidelines [5]. RPE benefits are to achieve the maximal 
tumor reduction and following pathological examination that allows to select patients who need 
adjuvant treatment. Prospective studies in this area allow only overall treatment strategies of this 
group of patients [6, 7]. 
Most of the studies devoted to the evaluation of oncological outcomes of RPE, RT or multi-
modality treatment of patients with locally advanced PCa face the challenge of heterogeneity with-
in this group [8, 9]. When the most of these patients have the benefits of treatment, some patients 
die, despite the chosen option. Thus, it is necessary to review the current classification system and 
develop optimal stratification of locally advanced PCa.
2. Aim of research
To present the oncologic outcomes of RPE in patients with clinically locally advanced PCa 
and create a model of its prognostic stratification using combinations of accepted risk factors.
3. Material and methods
We identified and treated with RPE 106 patients with clinically locally advanced PCa 
(stage cT3N0M0 according to the 2010 TNM system) between August 2002 and June 2015 at State 
Institution ‘Institute of Urology of National Academy of Medical Sciences of Ukraine’.
Prostate biopsies were performed under transrectal ultrasound (TRUS) guidance, and pre-
treatment PSA was measured before digital rectal examination (DRE) or TRUS. A minimum of six 
biopsy cores was taken for each patient included in the study. All patients underwent a bone scan 
and a magnetic resonance imaging scan or pelvic computed tomography. Patients were excluded if 
they were found to have radiographic evidence of regional or distant metastatic disease. 
Clinical stage was assigned according to the TNM system of 7th edition (2010) [10]. Clinical 
stage cT3a was determined in cases of tumor invasion beyond the prostate capsule without inva-
sion of the seminal vesicles, cT3b – in cases of MRI or CT signs of tumor invasion in the seminal 
vesicles, cT4 – in case of tumor invasion in the external sphincter. Table 1 presents the baseline 
characteristics of studying patients.
Out of all 106 patients, 31 (29.2 %) underwent laparoscopic RPE and 75 (70.8 %) underwent 
radical retropubic prostatectomy both with extended bilateral pelvic lymph node dissection. The 
RPE specimens including prostate, seminal vesicles, and bilateral pelvic lymph nodes were exam-
ined microscopically after routine preparation. The prostate was inked, weighted, and cut at 5-mm 
intervals. A positive surgical margin was defined as the presence of cancer cells extending into the 
inked surface of the prostate. A positive lymph node was defined as the presence of tumoral glands 
in at least one of the pelvic lymph nodes.
Follow-up included DRE, serum PSA measurement. Bone scan, MRI or CT were performed 
by indications. The serum PSA level was typically measured at 4 weeks and quarterly during the 
initial 2 years after surgery, semi-annually for an additional 3 years, and annually thereafter. Bio-
chemical recurrence (BCR) was defined as evaluation of total PSA by >0.2 ng/ml. Biochemical re-
currence free survival (BRFS) referred to time from RPE to biochemical reccurence constatation. 
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PCa-specific survival (PCSS) referred to time from RPE to death attributed to PCa or disease-re-
lated complications. Adjuvant therapy was defined as treatment received ≤90 days of RP, and was 
given at the discretion of the treating physician, while salvage therapy was defined as treatment 
received >90 days after RPE, and triggered by PSA recurrence or clinical progression.
The Kaplan-Meier method was used to estimate time-to-event outcomes and the log-rank 
method was used to compare survival. Cox proportional hazard regression was used to identify 
prognostic factors, which were employed in a stepwise selection approach. The assumption of pro-
portional hazards was confirmed for each of the input variables. All P values are two-sided, and a 
level of 0.05 was considered statistically significant.
Table 1
Characteristics of the study population
Characteristic Result
Mean age (range), years 62.2±0.6 (40–74)
Time of follow-up, months 55.7±3.2 (12–129)
Mean PSA (range), ng/ml 29.4±1.3 (2.5–150)
PSA<10 ng/ml, n (%) 8 (7.5)
PSA =10–20 ng/ml, n (%) 31 (29.2)
PSA >20 ng/ml, n (%) 67 (63.2)
Mean biopsy Gleason score 6.7 (5–9)
Gleason score 2–6, n (%) 49 (46.2)
Gleason score 7, n (%) 36 (34.0)
Gleason score 8–10, n (%) 21 (19.8)
Stage сТ
3а
, n (%) 52 (49.1 %)
Stage сТ3b, n (%) 55 (51.9 %)
Stage сТ4, n (%) 1 (0.9 %)
 
4. Results
Mean follow-up after RPE was 55.7±3.2 months, and 45 (42.5 %) patients had follow-up 
beyond 5 years. During the follow-up 55 (51.9 %) patients experienced biochemical recurrence, 18 
died, with 16 dying of PCa. Fig. 1 displays the BRFS and Fig. 2 – PCSS for the entire cohort of 
clinically locally advanced PCa patients.
In univariable analysis the most important predictor of  biochemical recurrence was clinical 
signs of tumor invasion in the seminal vesicles (hazard ratio (HR): 6.5; 95 % confidence interval 
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(CI), 2.8−13.3) followed by biopsy Gleason score ≥7 (HR: 1.7; 95 % CI, 0.8−3.6) and PSA ≥20 ng/ml 
(HR: 2.0; 95 % CI, 0.9−4.5).
On the basis of the three main clinical risk factors were established model of prognostic strat-
ification of clinically locally advanced PCa into three subgroups: low, intermediate and high risk. 
Low risk patients had PSA level <20 ng/ml, biopsy Gleason score ≤6 and absence of the 
seminal vesicle invasion of cancer (14 patients). Intermediate risk was noted when the patient had 
only one of poor  prognostic factors (PSA ≥20 ng/ml or biopsy Gleason scor e≥7 or presence of 
cancer invasion to the seminal vesicle, 35 patients) and high risk patients had 2 or 3 poor prognostic 
factors (57 patients).
Oncological outcomes and pathomorphological features of tumors were significantly dif-
ferent in all three subgroups. For patients of low, intermediate and high risk the biochemical rec-
curence rates were 14.3 %, 37.1 % and 70.2 %, respectively (p=0.002) (Fig. 3), and the risk of its 
development in patients with intermediate risk grew 3.0, high − in 8.5 times.
Fig. 1. Biochemical recurrence-free survival for the entire cohort of  
clinically locally advanced PCa patients
Proposed model demonstrated that most patients in low risk group were treated with RPE 
alone (adjuvant RT received 14.3 % of patients, adjuvant ADT − 26.8 %, and biochemical recur-
rence had only 2 of 14 patients (14.3 %)). In addition, 35.7 % of patients had pathologically or-
gan-confined prostate cancer that occurred clinical overstaging of the disease. 
On the other hand, a large number of high risk patients had poor pathomorphological char-
acteristics of tumor. Positive surgical margin identified in 49.1 % of cases, perineural invasion − in 
56.1 %, regional lymph nodes metastases − in 29.8 %. Most of patients in high risk group require 
multimodal treatment (adjuvant RT carried 40.4 % of patients, adjuvant ADT − 59.6 %) and had 
biochemical recurrence (40 of 57 patients, 70.2 %) (Table 2).
Obviously, the high-risk group includes patients with aggressive disease, regardless of the 
chosen treatment strategy. These patients should be in focus of the researchers of new treatment 
approaches of PCa.
The ambiguous place of intermediate risk in determining of optimal treatment option. Giv-
en the fact that 62.9 % of patients had no biochemical recurrence during the follow-up, adjuvant 
RT carried only 22.9 %, adjuvant ADT − 34.3 % of patients, and the frequency of poor prognostic 
features was lower than in the high-risk group, this group of patients can be offered RPE as a first-
line method of treatment. Feasibility of adjuvant therapy should be decided after determining the 
pathological tumor characteristics.
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Table 2
Pre- and postoperative patient characteristics related to prognostic subgroups
Characteristics
Risk group
р
Low,  
n=14
Intermediate, 
n=35
High,  
n=57
Mean age (range), years 64.4±1.6 61.8±1.0 61.9±0.8 0.351
Mean PSA level (range), ng/ml 13.0±1.1 23.8±1.9 36.9±3.6 0.0002
Mean Pathologic Gleason score 6.3 6.6 7.7
0.0001
Pathologic Gleason score ≤6, n (%) 9 (64.3) 18 (51.4) 5 (8.8)
Pathologic Gleason score 7, n (%) 3 (21.4) 13 (37.1) 31 (54.4)
Pathologic Gleason score ≥8, n (%) 2 (14.3) 4 (11.4) 21 (36.8)
Pathologic stage
0.0001
рТ2, n (%) 5 (35.7) 11 (31.4) 4 (7.0)
рТ
3а
, n (%) 4 (28.6) 15 (42.9) 9 (15.8)
рТ
3в
, n (%) 4 (28.6) 8 (22.9) 37 (64.9)
рТ4, n (%) 1 (7.1) 1 (2.9) 7 (12.3)
Lymph node methastasis, n (%) 0 4 (11.4) 17 (29.8) 0.014
Perineural invasion, n (%) 5 (35.7) 15 (42.8) 32 (56.1) 0.262
Positive surgical margin, n (%) 1 (7.1) 8 (22.9) 28 (49.1) 0.002
Adjuvant RT, n (%) 1 (7.1) 8 (22.9) 23 (40.4) 0.027
Adjuvant ADT, n (%) 4 (28.6) 12 (34.3) 34 (59.6) 0.020
Salvage RT, n (%) 0 4 (11.4) 4 (7.0) 0.383
Salvage ADT, n (%) 2 (14.3) 5 (14.3) 9 (15.8) 0.977
Biochemal recurrence rate, n (%) 2 (14.3) 13 (37.1) 40 (70.2) 0.0001
Cancer specific deaths rate, n (%) 1 (7.1) 4 (11.4) 11 (19.3) 0.02
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Fig. 2. Cancer-specific survival for the entire cohort of clinically locally advanced PCa patients
 
Fig. 3. Biochemical recurrence-free survival for the model of prognostic stratification of  
clinically locally advanced PCa with three prognostic subgroups
5. Discussion
Despite the clinical stage migration that has occurred with the advent of PSA screening, 
some patients continue to present with clinically locally advanced PCa [11]. The optimal treatment 
for this category of  men remains controversial and is a matter of debate [12, 13]. 
The data on surgical management of locally advanced PCa has not been investigated or sys-
tematically reviewed and no large randomized controlled trial is available to show its superiority. 
Comparison of RPE with other treatment options for locally advanced PCa is questionable due to pa-
tients heterogenity and inherent selection bias of good prognosis patients in favor of surgery [8, 9, 14]. 
A few studies have shown promising results of  RPE for locally advanced PCa [15, 16]. 
Xylinas et al. have shown oncologic outcomes in patients with T3 stage of PCa in few series of 
RPE. This meta-analysis has demonstrated 5-years BCRF, CSS and overall survival at 45−62 %, 
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84−98 % and 84−91 %, respectively [17]. Oncological outcomes of our study are similar to those 
reported in the literature series for clinically locally advanced PCa.
At diagnosis, PCa is usually classified into major risk categories based on TNM clinical 
stage, biopsy Gleason score and PSA level. It is generally assumed that patients with locally ad-
vanced PCa are at an elevated risk of experiencing biochemical recurrence, metastatic progression, 
and death from PCa [8, 18−20]. Our proposed model of prognostic stratification for patients with 
clinically locally advanced PCa was designed for use in clinical practice and comprises three prog-
nostic subgroups: a low, intermediate and high risk. BCR rates and histopathologic features at RP 
were significantly different between the low, intermediate and high risk subgroups.
Also, proposed model demonstrates that many patients of low risk were treated with sur-
gery alone and experienced exceptionally good 5-yr BRFS (85.7 %) and PCSS (92.8 %). Converse-
ly, most individuals in the high risk subgroup necessitated a multimodal treatment (adjuvant RT: 
40.4 %; adjuvant ADT: 59.6 %). Despite this much more intense treatment, 5-yr BRFS was sig-
nificantly worse (29.8 %). Clearly, the subgroup of high risk patients includes men with aggressive 
disease despite more intense treatment. Ideally, these patients should be in target when studying 
new combined treatment approaches.
6. Conclusions
1. Patients with clinically locally advanced prostate cancer have higher risk of biochemical 
failure after radical prostatectomy but demonstrate good cancer-specific and overall survival.
2. The proposed stratification of locally advanced prostate cancer into three prognostic 
groups of low, intermediate and high risk is easy in use by urologists and researchers for selecting 
the optimal treatment strategy. 
3. The patients of intermediate and high risk had clinically significant higher risk of bio-
chemical reccurence than those of low risk with odds ratio 3.0 and 8.5, respectively. 
4. The most of low risk patients can be treated with radical prostatectomy alone. 
5. The most of patients in high risk has an aggressive disease, need for multimodality treat-
ment and should be in focus of the researchers of new treatment approaches of prostate cancer.
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